ALLK - アラコス (Allakos Inc.)

ALLKのニュース

   Allakos announces $250M shelf offering  2022/05/06 21:36:03 Seeking Alpha
Allakos (ALLK) declines 1.5% during after hours on $250M worth shares shelf offering.Company will determine when they sell shares of our common stock, which may be sold on a continuous…
   Allakos GAAP EPS of -$3.60 misses by $1.78  2022/05/06 20:08:33 Seeking Alpha
Allakos press release (ALLK): Q1 GAAP EPS of -$3.60 misses by $1.78.Allakos ended the first quarter of 2022 with $246.7 million in cash, cash equivalents and marketable securities.
   Allakos Provides Business Update and Reports First Quarter 2022 Financial Results  2022/05/06 20:05:00 GlobeNewswire
REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022.
   CBAY, ALLK and SOND among after hour movers  2022/04/22 21:28:43 Seeking Alpha
Gainers: Evelo Biosciences, Inc. (EVLO) +5%. CymaBay Therapeutics Inc. (CBAY) +5%
   Allakos Inc. (NASDAQ:ALLK) Plunging -94.71% In 6 Months – Here’s What To Expect  2022/03/26 18:00:00 Marketing Sentinel
Allakos Inc. (NASDAQ:ALLK)’s traded shares stood at 0.63 million during the last session, with the company’s beta value hitting 0.72. At the close of trading, the stock’s price was $5.72, to imply a decrease of -4.03% or -$0.24 in intraday trading. The ALLK share’s 52-week high remains $116.61, putting it -1938.64% down since that peak … Allakos Inc. (NASDAQ:ALLK) Plunging -94.71% In 6 Months – Here’s What To Expect Read More »
   Allakos Inc Shares Fall 1.5% Below Previous 52-Week Low - Market Mover  2022/01/15 01:40:23 Kwhen Finance
Allakos Inc (ALLK) shares closed 1.5% lower than its previous 52 week low, giving the company a market cap of $426M. The stock is currently down 19.8% year-to-date, down 93.6% over the past 12 months, and down 74.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 77.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 236.3% The company's stock price performance over the past 12 months lags the peer average by 358.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Why Allakos Stock Plummeted 87.5% in the Last Month of 2021  2022/01/06 13:17:06 The Motley Fool
The biotech stock is now down roughly 93% over the last year.
   Allakos Inc Shares Close the Day 22.2% Higher - Daily Wrap  2021/12/27 09:55:48 Kwhen Finance
Allakos Inc (ALLK) shares closed today 22.2% higher than it did at the end of yesterday. The stock is currently down 92.5% year-to-date, down 93.1% over the past 12 months, and down 66.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $84.94 and as low as $8.44 this week.Shares closed 93.4% below its 52-week high and 23.8% above its 52-week low.Trading volume this week was 52.7% higher than the 10-day average and 593.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 862.6% The company's stock price performance over the past 12 months lags the peer average by 689.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Allakos Inc Shares Close the Day 22.2% Higher - Daily Wrap  2021/12/26 11:01:01 Kwhen Finance
Allakos Inc (ALLK) shares closed today 22.2% higher than it did at the end of yesterday. The stock is currently down 92.5% year-to-date, down 93.1% over the past 12 months, and down 66.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $84.94 and as low as $8.44 this week.Shares closed 93.4% below its 52-week high and 23.8% above its 52-week low.Trading volume this week was 89.7% higher than the 10-day average and 593.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 862.6% The company's stock price performance over the past 12 months lags the peer average by 689.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   The Goldman Sachs Group Lowers Allakos (NASDAQ:ALLK) Price Target to $60.00  2021/12/24 09:18:41 Transcript Daily
Allakos (NASDAQ:ALLK) had its target price decreased by The Goldman Sachs Group from $122.00 to $60.00 in a research report report published on Thursday morning, Analyst Ratings Network reports. The Goldman Sachs Group currently has a neutral rating on the stock. A number of other analysts have also commented on ALLK. Jefferies Financial Group lowered []
   LifeSci Capital Stick to Their Buy Rating for Allakos Inc By Investing.com  2021/03/09 09:06:34 Investing.com
LifeSci Capital Stick to Their Buy Rating for Allakos Inc
   Leerink Partners Stick to Their Buy Rating for Allakos Inc By Investing.com  2021/03/02 14:48:10 Investing.com
Leerink Partners Stick to Their Buy Rating for Allakos Inc
   Allakos Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2021/03/01 22:05:00 Stock Market Daily
Allakos announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts  2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.
   The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica  2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.

calendar